- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
No change in FDA approval time despite new technology, study shows
Even given implementation of information technology, FDA drug approval time has not decreased, according to researchers.
Despite increased use of information technology, FDA drug approval time is still not shorter, according to scientists.
Associate Professor John Kros and Assistant Professor Christopher Keller of East Carolina University, said FDA has implemented new information technology in an effort to reduce the time required between the submission of a new drug application, and final approval.
Although the 1992 Prescription Drug User Fee Act required drug companies to pay fees to the FDA in return for an agreement to set time limits on the review process for new drug applications, the scientists said their study found no statistically significant reduction in approval intervals from 1997 to 2006.“The present research contributes a baseline for future comparison by which any future reductions in approval times which … result from the implementation of information technology could be verified,” the researchers said.
Their findings appear in the International Journal of Electronic Healthcare.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
